Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akcea Therapeutics Inc (AKCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,683,884
  • Shares Outstanding, K 89,433
  • Annual Sales, $ 64,870 K
  • Annual Income, $ -225,820 K
  • 60-Month Beta 1.71
  • Price/Sales 40.62
  • Price/Cash Flow N/A
  • Price/Book 9.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.24
  • Number of Estimates 3
  • High Estimate 1.94
  • Low Estimate 0.51
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +381.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.82 +21.35%
on 02/19/19
35.82 -15.91%
on 02/28/19
+2.43 (+8.78%)
since 02/15/19
3-Month
24.82 +21.35%
on 02/19/19
35.82 -15.91%
on 02/28/19
+0.85 (+2.90%)
since 12/18/18
52-Week
17.74 +69.79%
on 05/08/18
40.75 -26.09%
on 08/07/18
-1.09 (-3.49%)
since 03/16/18

Most Recent Stories

More News
Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that data from the NEURO-TTR open-label extension study...

AKCA : 30.12 (+0.37%)
IONS : 79.52 (+1.25%)
Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT),...

ELLI : 98.94 (+0.27%)
SRPT : 126.82 (-1.20%)
AKCA : 30.12 (+0.37%)
SBH : 18.14 (+2.08%)
BCRX : 8.12 (+0.74%)
DHR : 128.07 (-0.48%)
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Committee for Medicinal Products for Human...

AKCA : 30.12 (+0.37%)
IONS : 79.52 (+1.25%)
Akcea(R) Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced the...

AKCA : 30.12 (+0.37%)
IONS : 79.52 (+1.25%)
Akcea Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Akcea Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at 4:30...

AKCA : 30.12 (+0.37%)
Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)

Novartis International AG / Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a) . Processed and transmitted...

AKCA : 30.12 (+0.37%)
IONS : 79.52 (+1.25%)
NVS : 93.17 (-0.13%)
AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License

Phase 3 planning and initiation activities underway

AKCA : 30.12 (+0.37%)
IONS : 79.52 (+1.25%)
Akcea Therapeutics to Present at Upcoming Investor Conferences

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that...

AKCA : 30.12 (+0.37%)
IONS : 79.52 (+1.25%)
Detailed Research: Economic Perspectives on Yelp, Jabil, SBA Communications, comScore, AVX, and Akcea Therapeutics -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Yelp Inc. (NYSE:YELP), Jabil,...

AVX : 17.99 (-0.72%)
JBL : 26.89 (-1.03%)
SCOR : 21.89 (-1.93%)
AKCA : 30.12 (+0.37%)
SBAC : 191.56 (+0.32%)
YELP : 34.88 (-0.63%)
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast

Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, February 26 at 4:30 p.m. Eastern Time to discuss its fourth...

AKCA : 30.12 (+0.37%)
IONS : 79.52 (+1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade AKCA with:

Business Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx...

See More

Key Turning Points

2nd Resistance Point 31.94
1st Resistance Point 31.03
Last Price 30.12
1st Support Level 28.96
2nd Support Level 27.80

See More

52-Week High 40.75
Fibonacci 61.8% 31.96
Last Price 30.12
Fibonacci 50% 29.24
Fibonacci 38.2% 26.53
52-Week Low 17.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar